Carotech showcases latest liver and brain health studies at Ingredient Marketplace 2014
Tocomin SupraBio found to improve fatty liver in non-alcoholic fatty liver disease
Carotech will exhibit and share two of the latest human clinical study results on its flagship product Tocomin SupraBio, a bioenhanced full spectrum palm tocotrienol complex for liver and brain health at Ingredient Marketplace 2014 (New York, US, 2–3 June).
Two recent human clinical studies provided 'strong and significant' evidence that oral supplementation with Tocomin SupraBio improves fatty liver in non-alcoholic fatty liver disease (NAFLD) and attenuates the progression of white matter lesions (WMLs) in human brain, the company says.
'According to renowned hepatologist Dr Michael Curry of the Beth Israel Deaconess Medical Center in Boston, a third of the US population has NAFLD, which currently has no cure,' says Bryan See, Regional Product Manager at Carotech. 'Furthermore, NAFLD has been recognised as the precursor for metabolic syndrome-related diseases such as obesity, hypertension and diabetes. And some of these subjects will go on to develop cirrhosis and end-stage liver disease. NAFLD is the common thread that connects all these debilitating health conditions. This really underscores the need to address NAFLD and nip it in the bud before one develops these metabolic syndromes that ultimately lead to severe liver disease.'
Another health benefit of Tocomin SupraBio is said to be its neuroprotection effects. Researchers at Ohio State University Medical Center have been studying the neuroprotective property of palm tocotrienol complex (Tocomin SupraBio). A recent human clinical study, conducted at the University Science of Malaysia showed that supplementation with Tocomin SupraBio attenuates the progression of brain white matter lesions (WMLs), which are often linked to vascular events of the brain and are an indication of fragile brain vascular network. WMLs are also linked to increased stroke risk and development of other neurodegenerative disease.
'We are excited about these newly published clinical studies and are looking forward to sharing and discussing potential formulations and concepts with nutritional supplement companies or marketers at Ingredient Marketplace,'adds See.
